The valproate serum level in maintenance therapy for bipolar disorder in Japan.

Q4 Medicine
Akihiko Machino, Hiroaki Jitsuiki, Yasumasa Okamoto, Satoru Izumitani, Yasuhiro Kimura, Katsuji Suzuki, Teruaki Tanaka, Takeshi Inoue, Tsukasa Koyama, Ken Wada, Yukari Masaoka, Takanobu Sasaki, Reiji Yoshimura, Jun Nakamura, Satsuki Sumitan, Tetsuro Ohmori, Shigeto Yamawaki
{"title":"The valproate serum level in maintenance therapy for bipolar disorder in Japan.","authors":"Akihiko Machino,&nbsp;Hiroaki Jitsuiki,&nbsp;Yasumasa Okamoto,&nbsp;Satoru Izumitani,&nbsp;Yasuhiro Kimura,&nbsp;Katsuji Suzuki,&nbsp;Teruaki Tanaka,&nbsp;Takeshi Inoue,&nbsp;Tsukasa Koyama,&nbsp;Ken Wada,&nbsp;Yukari Masaoka,&nbsp;Takanobu Sasaki,&nbsp;Reiji Yoshimura,&nbsp;Jun Nakamura,&nbsp;Satsuki Sumitan,&nbsp;Tetsuro Ohmori,&nbsp;Shigeto Yamawaki","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The appropriate therapeutic serum valproate level in maintenance therapy for bipolar disorder is not well known. We studied the serum valproate levels in seventeen bipolar I and twenty-four bipolar II disorder outpatients who had been treated with stable doses of valproate successfully for at least 12 months as prophylactic therapy. The trough serum valproate levels were 52.2 +/- 20.4 microg/ml in bipolar I, and 41.0 +/- 18.3 microg/ml in bipolar II disorder patients, respectively. A greater trend towards a higher trough level (p = 0.07) was indicated in the bipolar I disorder group. We speculate that these valproate levels may be an approximation to the appropriate valproate levels in maintenance therapy and that there may be a correlation between the level of valproate required for stabilization and the subtype of the bipolar disorder. However, when interpreting these findings, certain limitations to this study? Need to be taken into account as follows. The sample size was small. We could not look at a group on valproate that had relapsed and a group that had dropped out of maintenance therapy. Further studies are needed.</p>","PeriodicalId":12860,"journal":{"name":"Hiroshima journal of medical sciences","volume":"62 1","pages":"7-12"},"PeriodicalIF":0.0000,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hiroshima journal of medical sciences","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The appropriate therapeutic serum valproate level in maintenance therapy for bipolar disorder is not well known. We studied the serum valproate levels in seventeen bipolar I and twenty-four bipolar II disorder outpatients who had been treated with stable doses of valproate successfully for at least 12 months as prophylactic therapy. The trough serum valproate levels were 52.2 +/- 20.4 microg/ml in bipolar I, and 41.0 +/- 18.3 microg/ml in bipolar II disorder patients, respectively. A greater trend towards a higher trough level (p = 0.07) was indicated in the bipolar I disorder group. We speculate that these valproate levels may be an approximation to the appropriate valproate levels in maintenance therapy and that there may be a correlation between the level of valproate required for stabilization and the subtype of the bipolar disorder. However, when interpreting these findings, certain limitations to this study? Need to be taken into account as follows. The sample size was small. We could not look at a group on valproate that had relapsed and a group that had dropped out of maintenance therapy. Further studies are needed.

日本双相情感障碍维持治疗中的丙戊酸血清水平。
在双相情感障碍维持治疗中,合适的血清丙戊酸水平尚不清楚。我们研究了17例I型双相情感障碍和24例II型双相情感障碍门诊患者的血清丙戊酸水平,这些患者都成功地接受了稳定剂量的丙戊酸作为预防治疗至少12个月。双相情感障碍I型和II型患者的谷底丙戊酸水平分别为52.2 +/- 20.4微克/毫升和41.0 +/- 18.3微克/毫升。双相I型障碍组有更高低谷水平的趋势(p = 0.07)。我们推测这些丙戊酸水平可能是维持治疗中适当丙戊酸水平的近似值,并且稳定所需的丙戊酸水平与双相情感障碍亚型之间可能存在相关性。然而,在解释这些发现时,本研究的某些局限性?需要考虑的因素如下。样本量很小。我们不能观察服用丙戊酸盐的一组复发和一组退出维持治疗的人。需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hiroshima journal of medical sciences
Hiroshima journal of medical sciences Medicine-Medicine (all)
CiteScore
0.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书